Anti-platelets in diabetes management

N. M. Grantham, D. J. Magliano, G. Tai, N. Cohen, J. E. Shaw

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

This study aimed to determine the prevalence of anti-platelet use, and the extent to which contraindications to anti-platelet therapy prevent its use, in 726 diabetic patients attending a private clinic. Among those who reported a history of cardiovascular disease (CVD), 87.1% were on anti-platelet therapy. Of those without prior CVD but with at least one CVD risk factor, 59.8% were not on anti-platelet therapy, but only 7.1% of these had a contraindication to anti-platelet therapy. This study showed that high usage of anti-platelet therapy in diabetic patients with prior CVD is achievable, and that contraindications did not explain low use in those without prior CVD.

Original languageEnglish
Pages (from-to)458-462
Number of pages5
JournalInternal Medicine Journal
Volume40
Issue number6
DOIs
Publication statusPublished - Jun 2010
Externally publishedYes

Keywords

  • Aspirin
  • Cardiovascular disease
  • Complications
  • Diabetes mellitus
  • Prevention and control
  • Type 2

Cite this

Grantham, N. M. ; Magliano, D. J. ; Tai, G. ; Cohen, N. ; Shaw, J. E. / Anti-platelets in diabetes management. In: Internal Medicine Journal. 2010 ; Vol. 40, No. 6. pp. 458-462.
@article{40e9737ce8ab4a2eb7b864384f341298,
title = "Anti-platelets in diabetes management",
abstract = "This study aimed to determine the prevalence of anti-platelet use, and the extent to which contraindications to anti-platelet therapy prevent its use, in 726 diabetic patients attending a private clinic. Among those who reported a history of cardiovascular disease (CVD), 87.1{\%} were on anti-platelet therapy. Of those without prior CVD but with at least one CVD risk factor, 59.8{\%} were not on anti-platelet therapy, but only 7.1{\%} of these had a contraindication to anti-platelet therapy. This study showed that high usage of anti-platelet therapy in diabetic patients with prior CVD is achievable, and that contraindications did not explain low use in those without prior CVD.",
keywords = "Aspirin, Cardiovascular disease, Complications, Diabetes mellitus, Prevention and control, Type 2",
author = "Grantham, {N. M.} and Magliano, {D. J.} and G. Tai and N. Cohen and Shaw, {J. E.}",
year = "2010",
month = "6",
doi = "10.1111/j.1445-5994.2010.02232.x",
language = "English",
volume = "40",
pages = "458--462",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "6",

}

Anti-platelets in diabetes management. / Grantham, N. M.; Magliano, D. J.; Tai, G.; Cohen, N.; Shaw, J. E.

In: Internal Medicine Journal, Vol. 40, No. 6, 06.2010, p. 458-462.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Anti-platelets in diabetes management

AU - Grantham, N. M.

AU - Magliano, D. J.

AU - Tai, G.

AU - Cohen, N.

AU - Shaw, J. E.

PY - 2010/6

Y1 - 2010/6

N2 - This study aimed to determine the prevalence of anti-platelet use, and the extent to which contraindications to anti-platelet therapy prevent its use, in 726 diabetic patients attending a private clinic. Among those who reported a history of cardiovascular disease (CVD), 87.1% were on anti-platelet therapy. Of those without prior CVD but with at least one CVD risk factor, 59.8% were not on anti-platelet therapy, but only 7.1% of these had a contraindication to anti-platelet therapy. This study showed that high usage of anti-platelet therapy in diabetic patients with prior CVD is achievable, and that contraindications did not explain low use in those without prior CVD.

AB - This study aimed to determine the prevalence of anti-platelet use, and the extent to which contraindications to anti-platelet therapy prevent its use, in 726 diabetic patients attending a private clinic. Among those who reported a history of cardiovascular disease (CVD), 87.1% were on anti-platelet therapy. Of those without prior CVD but with at least one CVD risk factor, 59.8% were not on anti-platelet therapy, but only 7.1% of these had a contraindication to anti-platelet therapy. This study showed that high usage of anti-platelet therapy in diabetic patients with prior CVD is achievable, and that contraindications did not explain low use in those without prior CVD.

KW - Aspirin

KW - Cardiovascular disease

KW - Complications

KW - Diabetes mellitus

KW - Prevention and control

KW - Type 2

UR - http://www.scopus.com/inward/record.url?scp=77953823898&partnerID=8YFLogxK

U2 - 10.1111/j.1445-5994.2010.02232.x

DO - 10.1111/j.1445-5994.2010.02232.x

M3 - Article

VL - 40

SP - 458

EP - 462

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 6

ER -